<DOC>
	<DOCNO>NCT00926289</DOCNO>
	<brief_summary>The primary objective trial demonstrate fixed-dose combination T80/HCTZ25 superior first line therapy reduce seat trough cuff Systolic Blood Pressure ( SBP ) compare monotherapy T80 patient grade 2 grade 3 hypertension ( SBP &gt; =160 mmHg Diastolic Blood Pressure ( DBP ) &gt; =100 mmHg ) .</brief_summary>
	<brief_title>Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line Moderate Severe Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion criterion : 1 . Ability provide write informed consent accordance Good Clinical Practice local legislation ; 2 . Age 18 year old ; 3 . Patients grade 2 grade 3 hypertension define SBP &gt; =160 mmHg DBP &gt; =100 mmHg randomization 4 . Ability stop current antihypertensive therapy without unacceptable risk patient ( Investigator 's discretion ) Exclusion criterion : 1 . Premenopausal woman ( last menstruation &lt; =1 year prior sign informed consent ) : ) surgically sterile ; b ) nursing , c ) pregnant , ) childbearing potential NOT practice acceptable method birth control , NOT plan continue practice acceptable method throughout trial . The acceptable method birth control : IntraUterine Device ( IUD ) , Oral contraceptive , Implantable injectable contraceptive , Estrogen patch Hormonal birth control use least three month study continue least next menstrual period complete study . 2 . Night shift worker routinely sleep daytime whose work hour include midnight 4:00 a.m. 3 . Known suspected secondary hypertension ( e.g. , renal artery stenosis orphaeochromocytoma ) 4 . Mean inclinic seat cuff SBP &gt; = 200 mmHg and/or DBP &gt; =120 mmHg 5 . Renal dysfunction define follow laboratory parameter : Serum creatinine &gt; 3.0 mg/dL ( &gt; 265 umol/L ) and/or know creatinine clearance &lt; 30 ml/min and/or clinical marker severe renal impairment . 6 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , postrenal transplant patient patient one kidney 7 . Clinically relevant hypokalemia hyperkalemia ( i.e. , &lt; 3.5 mmol/L &gt; 5.5 mmol/L , may rechecked suspected error result ) 8 . Uncorrected sodium volume depletion 9 . Primary aldosteronism . 10 . Hereditary fructose intolerance 11 . Biliary obstructive disorder ( e.g. , cholestasis ) hepatic insufficiency 12 . Congestive heart failure New York Heart Association functional class Congestive Heart Failure IIIIV ( Refer Appendix 10.3 ) 13 . Contraindication placebo runin period ( e.g. , stroke within past 6 month , myocardial infarction , cardiac surgery , percutaneous transluminal coronary angioplasty , unstable angina coronary artery bypass graft within past 3 month prior start run period ) 14 . Clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine Investigator 15 . Hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve 16 . Patients whose diabetes stable control least past 3 month define Glycosylated Hemoglobin &gt; =10 % 17 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensinII receptor antagonist 18 . History drug alcohol dependency within 6 month prior sign inform consent form 19 . Concomitant administration medication know affect blood pressure , except medication allow protocol 20 . Any investigational drug therapy within 1 month signing inform consent 21 . Known hypersensitivity component trial drug ( telmisartan , hydrochlorothiazide , placebo ) 22 . History noncompliance inability comply prescribed medication protocol procedure ( less 80 % 120 % , especially runin ) 23 . Any clinical condition , opinion investigator , would allow safe completion protocol safe administration trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>